Search results for "nesidioblastosis"

showing 4 items of 4 documents

The treatment of hyperinsulinemic hypoglycaemia in adults: an update

2016

Treatment of hyperinsulinemic hypoglycaemia (HH) is challenging due to the rarity of this condition and the difficulty of differential diagnosis. The aim of this article is to give an overview of the recent literature on the management of adult HH. A search for reviews, original articles, original case reports between 1995 and 2016 in PubMed using the following keywords: hyperinsulinemic hypoglycaemia, insulinoma, nesidioblastosis, gastric bypass, autoimmune hypoglycaemia, hyperinsulinism, treatment was performed. One hundred and forty articles were selected and analysed focusing on the most recent treatments of HH. New approaches to treatment of HH are available including mini-invasive sur…

Adultmedicine.medical_specialtyPediatricsendocrine system diseasesEndocrinology Diabetes and MetabolismGastric bypassNesidioblastosis030209 endocrinology & metabolismHypoglycemiaSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyHyperinsulinismmedicineHyperinsulinemic hypoglycaemiaHumansAutoimmune hypoglycaemiaInsulinomaEverolimusbusiness.industryAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment; Adult; Humans; Hyperinsulinism; HypoglycemiaAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment; Adult; Humans; Hyperinsulinism; Hypoglycemia; Endocrinology Diabetes and Metabolism; EndocrinologySettore MED/13 - ENDOCRINOLOGIANesidioblastosimedicine.diseaseHypoglycemiaSurgeryDiabetes and MetabolismTreatmentNesidioblastosisAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment030220 oncology & carcinogenesisAutoimmune hypoglycaemiaInsulinomaAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment; Endocrinology Diabetes and Metabolism; EndocrinologyDifferential diagnosisbusinessHyperinsulinismhormones hormone substitutes and hormone antagonistsmedicine.drugHuman
researchProduct

Operative Therapie und Ergebnisse beim Insulinom

2001

In the therapy of organic hyperinsulinism, interest is mainly focussed on the surgical removal of the hyperactive tissue. In spite of these progresses, the surgical treatment is not devoid of problems. These comprise the primary untraceable insulinoma, multiple insulinomas, nesidioblastosis and reoperation. The development of laparoscopic surgery leads to new opportunities the rating of which must be defined. Solitary adenomas are causal for primary hyperinsulinism in 80% to 90% of cases. Intraoperative 87.5% of the tumors are palpable and 83% are detectable by ultrasound. By combination of both methods it is possible to remove 97% of the solitary tumors. Occult adenomas, which cannot be re…

Laparoscopic surgerymedicine.medical_specialtymedicine.diagnostic_testAdenomabusiness.industrymedicine.medical_treatmentNesidioblastosismedicine.diseasePalpationOccultEndocrine surgerymedicineSurgeryRadiologyLaparoscopybusinessInsulinomaZentralblatt für Chirurgie
researchProduct

The basic structural lesion of persistent neonatal hypoglycaemia with hyperinsulinism: deficiency of pancreatic D cells or hyperactivity of B cells?

1984

Pancreatic tissue obtained at subtotal pancreatectomy from 15 infants with persistent hypoglycaemia with hyperinsulinism, and autopsy specimens from 23 age-matched normoglycaemic controls, were studied with morphometric methods after immunocytochemical staining of the four main islet cell types (A, B, D and pancreatic polypeptide cells). In three cases, a focal lesion was detected by gross examination. Macroscopic or microscopic examination did not distinguish the 12 other cases from controls. As found previously, nesidioblastosis was not a specific feature of the pancreas in infantile hypoglycaemia, being observed in age-matched controls as well. In cases with hypoglycaemia the volume dens…

Malemedicine.medical_specialtyPancreatic Polypeptide-Secreting CellsCell typePathologyEndocrinology Diabetes and MetabolismNesidioblastosisCell CountLesionIslets of LangerhansInternal medicineHyperinsulinismInternal MedicinemedicineHumansB cellCell Nucleusbusiness.industryDegranulationInfant NewbornInfantmedicine.diseaseHypoglycemiaEndocrinologymedicine.anatomical_structureFemalemedicine.symptombusinessPancreasHyperinsulinismDiabetologia
researchProduct

Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion

2021

Introduction Inappropriate insulin secretion could be due to several diseases. Nesidioblastosis is characterized by diffuse hyperplasia of pancreatic beta cells, causing organic hypoglycemia. No pancreatic lesions are found on the imaging of patients with this condition. Diazoxide is used as a first-line treatment but can be poorly tolerated because of its side effects, and therapeutic failure is possible. Somatostatin analogues have limited efficacy because of their poor affinity to somatostatin (SST) receptors. Pasireotide is a somatostatin analogue with a much higher affinity to SST receptors, especially SST5, and it could thus be more efficient for treating nesidioblastosis-related hypo…

medicine.medical_specialtymedicine.medical_treatmentNesidioblastosisOctreotideCase ReportHypoglycemiaGastroenterologychemistry.chemical_compoundInternal medicinemedicineDiazoxidePharmacology (medical)business.industryInsulinnutritional and metabolic diseasesmedicine.diseasenesidioblastosisPasireotidediazoxideSomatostatinhypoglycemiachemistrySitagliptinpasireotide LARbusinessmedicine.drugClinical Pharmacology : Advances and Applications
researchProduct